Sentiment-Signal
25,9
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 08.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | K (the “Original Form 8-K”) reporting under Item 5.02 the resignation of R.A. Session II as the Company’s President and |
| 06.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 8-K (the “Original Form 8-K”) reporting under Item 5.02 the resignation of R.A. Session II as the Company’s President an |
Stammdaten
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Unternehmen & Branche
| Name | Taysha Gene Therapies, Inc. |
|---|---|
| Ticker | TSHA |
| CIK | 0001806310 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,57 Mrd. USD |
| Beta | 1,08 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 9,773,000 | -108,995,000 | -0.34 | 343,320,000 | 246,938,000 |
| 2025-09-30 | 10-Q | 0 | -32,733,000 | -0.09 | 316,554,000 | 218,989,000 |
| 2025-06-30 | 10-Q | 1,986,000 | -26,882,000 | -0.09 | 333,331,000 | 248,727,000 |
| 2025-03-31 | 10-Q | 2,302,000 | -21,529,000 | -0.08 | 138,362,000 | 55,059,000 |
| 2024-12-31 | 10-K | 8,333,000 | -89,298,000 | -0.36 | 160,364,000 | 71,525,000 |
| 2024-09-30 | 10-Q | 1,788,000 | -25,524,000 | -0.10 | 180,217,000 | 88,797,000 |
| 2024-06-30 | 10-Q | 1,112,000 | -20,928,000 | -0.09 | 200,393,000 | 108,868,000 |
| 2024-03-31 | 10-Q | 3,411,000 | -24,061,000 | -0.10 | 152,999,000 | 53,849,000 |
| 2023-12-31 | 10-K | 15,451,000 | -111,566,000 | -0.96 | 172,731,000 | 74,937,000 |
| 2023-09-30 | 10-Q | 4,746,000 | -117,087,000 | -0.93 | 195,769,000 | -49,114,000 |
| 2023-06-30 | 10-Q | 2,395,000 | -24,598,000 | -0.38 | 81,543,000 | -37,114,000 |
| 2023-03-31 | 10-Q | 4,706,000 | -17,622,000 | -0.28 | 101,600,000 | -14,948,000 |
| 2022-12-31 | 10-K | 2,502,000 | -166,014,000 | -3.78 | 126,276,000 | 949,000 |
| 2022-09-30 | 10-Q | -26,527,000 | -0.65 | 111,468,000 | 10,703,000 | |
| 2022-06-30 | 10-Q | -34,092,000 | -0.85 | 142,332,000 | 32,507,000 | |
| 2022-03-31 | 10-Q | -50,317,000 | -1.32 | 165,976,000 | 50,741,000 | |
| 2021-12-31 | 10-K | -174,523,000 | -4.64 | 213,956,000 | 95,383,000 | |
| 2021-09-30 | 10-Q | -51,187,000 | -1.35 | 241,042,000 | 140,394,000 | |
| 2021-06-30 | 10-Q | -40,926,000 | -1.09 | 241,860,000 | 186,495,000 | |
| 2021-03-31 | 10-Q | -32,024,000 | 242,829,000 | 222,872,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-10 | Nagendran Sukumar | Director, Officer, President and Head of R&D | Open Market Sale | -200,000 | 4.46 | -892,000.00 | -158,6% | |
| 2026-02-04 | Alam Kamran | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1,655 | 4.52 | -7,480.60 | -1,3% | |
| 2026-01-26 | Alam Kamran | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -23,849 | 4.61 | -109,943.89 | -19,5% | |
| 2026-01-26 | Nagendran Sukumar | Director, Officer, President and Head of R&D | Open Market Sale | -26,918 | 4.61 | -124,091.98 | -22,1% | |
| 2026-01-26 | Nolan Sean P. | Director, Officer, Chief Executive Officer | Open Market Sale | -41,312 | 4.61 | -190,448.32 | -33,9% | |
| 2026-01-23 | Alam Kamran | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -78,968 | 4.75 | -375,098.00 | -66,7% | |
| 2026-01-23 | Nolan Sean P. | Director, Officer, Chief Executive Officer | Open Market Sale | -136,789 | 4.75 | -649,747.75 | -115,5% | |
| 2026-01-23 | Nagendran Sukumar | Director, Officer, President and Head of R&D | Open Market Sale | -89,132 | 4.75 | -423,377.00 | -75,3% | |
| 2026-01-12 | Nagendran Sukumar | Director, Officer, President and Head of R&D | Open Market Sale | -200,000 | 4.71 | -942,000.00 | -167,5% | |
| 2025-12-01 | Nagendran Sukumar | Director, Officer, President and Head of R&D | Open Market Sale | -260,047 | 4.51 | -1,172,811.97 | -208,5% | |
| 2025-11-28 | Nagendran Sukumar | Director, Officer, President and Head of R&D | Open Market Sale | -110,125 | 4.75 | -523,093.75 | -93,0% | |
| 2025-09-10 | Nagendran Sukumar | Director, Officer, President and Head of R&D | Open Market Sale | -200,000 | 3.23 | -646,000.00 | -114,9% | |
| 2025-08-21 | Alam Kamran | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -54,491 | 2.85 | -155,299.35 | -27,6% | |
| 2025-08-21 | Nagendran Sukumar | Director, Officer, President and Head of R&D | Open Market Sale | -57,054 | 2.85 | -162,603.90 | -28,9% | |
| 2025-05-30 | Manning Paul B | 10% Owner | Open Market Purchase | 750,000 | 2.75 | 2,062,500.00 | +366,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.